Expression of Vascular Endothelial Growth Factor in Uveal Melanoma

A prerequisite for the growth, progression and metastasis of malignant tumors of any localization is the development of its own vascular network. Newly formed vessels not only nourish the primary tumor, but also create conditions for the spread of tumor cells through the circulatory system and the formation of distant metastases. Angiogenesis is able to launch a small population of tumors from 100–300 cells that have accumulated genetic aberrations and have begun to express proangigenic molecules. The phenomenon is known as “transformation of tumor cells into angiogenic phenotype”. A tumor with angiogenic phenotype carries a high potential for proliferation and malignization. This pattern has been found in many types of cancer, but studied less in uveal melanoma. Meanwhile, in this aspect, uveal melanoma, metastasizing exclusively in a hematogenic way, with its selective, organotropic nature of metastasis, becomes an attractive model for the study of the molecular “scenario” of tumor angiogenesis studies allow us to say that, UM is subject to the general patterns of the development of malignant tumors. As with many types of tumors, VEGF is an obligate condition for the development and progression of UM. The VEGF molecule’s producers in UM are two cell populations: endothelial vascular cells and tumor cells. VEGF’s expression in UM is cyclical. The cycle is re-initiated, apparently, by increasing cell density in tumor proliferate and the development of hypoxia zones. We found no correlation between the intensity of pigmentation, necrosis, hemorrhage, germination in the corner of the front chamber, ophthalmohypertension on the one hand, and expression of VEGF in UM cells on the other. At the same time, a direct link between the expression of VEGF in tumor cells and EC vessels on the one hand and the thickness, base diameter, as well as the localization of UM, on the other hand, has been revealed. Additionally, VEGF expression in tumor cells was closely correlated with the histological structure of UM, and VEGF expression in EC correlated with the stage of the disease. Thus, the authors showed that UM, like other malignant solid tumors, is prone to transformation into angiogenic phenotype and expression of VEGF.

1. Baryshnikov A.Yu., Stepanova E.V., Lichinitser M.R. Assessment of angiogenesis of human tumors. Advances in modern biology = Uspekhi sovremennoy biologii. 2000;120(6):599–604 (In Russ.).

2. Karamysheva A.F. Tumor angiogenesis: mechanisms, new approaches. In the book: Carcinogenesis. Ed. by D.G. Zaridze. Moscow: Scientific World, 2000 (In Russ.).

3. Ziangirova G.G.. Likhvantseva V.G. Tumors of the vascular tract of the eye. Moscow: The last word, 2003. 456 р. (In Russ.).

4. Lichtenstein A.V., Shapot V.S. Tumor growth: tissues, cells, molecules. Pathological physiology and experimental therapy = Patologicheskaya fiziologiya i eksperimental’naya terapiya. 1998;3:25–44 (In Russ.).

5. Kozlov D.V., Zorin N.A., Golubev O.A. Secondary angiogenesis is one of the links in the formation and progression of breast cancer. Archive of patholog = Arhiv patologii. 1996;58(4):72–75 (In Russ.).

6. Ferrara N. and Dans-Smyth T. The biology of vascular endothelial growth factor. Endocrine Revs. 1997;18(1):4–23. DOI: 10.1210/edrv.18.1.0287

7. Melincovici C.S., Boşca A.B., Şuşman S., Mărginean M., Mihu C., Istrate M. Vascular endothelial growth factor (VEGF) — key factor in normal and pathological angiogenesis. Rom J Morphol Embryol. 2018;59(2):455–467.

8. Folberg R., Pee’r J., Gruman L.M. The morfologic characteristics of tumor blood vessels as a marker of tumor progression in primary human uveal melanoma: a matched case-control study. Hum Pathol. 1992;23:1298–1305. DOI: 10.1016/00468177(92)90299-i

9. Folberg R., Rummelt V., Parys-Van Ginderdeuren R., Hwan T. The prognostic value of tumor blood vessel morphology in primary uveal melanoma. Ophthalmology. 1993;100:1389–1398. DOI: 10.1016/s0161-6420(93)31470-3

10. Folberg R. Tumor progression in ocular melanomas. J. Invest Dermatol. 1993;100(3):326S–333S. DOI: 10.1111/1523-1747.ep12470222

11. Folberg R.t, Menaffey M., Gardner L.M.The microcirculation of choroidal and ciliary body melanomas. Eye. 1997;11(2):227–238. DOI: 10.1038/eye.1997.57

12. Komolova G.S., Rustam’yan Yu.L. Angiogenin-induced angiogenesis as a target in tumor therapy. Experimental and Clinical Pharmacology = Eksperimental’naya i klinicheskaya farmakologiya. 1998;61(5):81–84 (In Russ.).

13. Kopnin B.P. Neoplastic cell: basic properties and mechanisms of their occurrence. Practical oncology = Prakticheskaya onkologiya. 2002;3(4):229–235 (In Russ.).

14. Stepanova E.V. Antiangiogenic therapy: new possibilities for the treatment of malignant diseases. Practical oncology = Prakticheskaya onkologiya. 2002;3(4):246– 252 (In Russ.).

15. Brierley J., Gospodarowicz M.K., Wittekind C. (eds.) TNM classification of malignant tumours, Eighth edition edn. Oxford, UK; Hoboken, N.J.: John Wiley & Sons, Inc; 2017.

16. Garg G., Finger P.T., Kivelä T.T., Simpson E.R., Gallie B.L., Saakyan S. Patients presenting with metastases: stage IV uveal melanoma, an international study. Br J Ophthalmol 2021;0:1–8. DOI: 10.1136/bjophthalmol-2020-317949

17. Heegaard S., Jensen O.A., Prause J.U. Immunohistochemical diagnosis of malignant melanoma of the conjunctiva and uvea: comparison of the novel antibody against melan-A with S100 protein and HMB-45. Melanoma Res. 2000;10(4):350–354. DOI: 10.1097/00008390-200008000-00006

18. Iwamoto S., Burrows R.C., Kalina R.E. Immunophenotypic differences between uveal and cutaneous melanomas. Arch Ophthalmol 2002;120(4):466–470 DOI: 10.1001/archopht.120.4.466

19. Ferrara N. Vascular Endothelial Growth Factor as a target for anticancer therapy. Oncologist. 2004;9(Suppl 1):2–10. DOI: 10.1634/theoncologist.9-suppl_1-2

20. el Filali M., Missotten G.S.O.A., Maat W., Ly L.V., Luyten G.P.M., van der Velden P.A., Jager M.J. Regulation of VEGF-A in uveal melanoma Invest Ophthalmol Vis Sci. 2010;51(5):2329–2337. DOI: 10.1167/iovs.09-4739

21. Boyd S.R., Tan D., Bunce C. Vascular endothelial growth factor is elevated in ocular fluids of eyes harbouring uveal melanoma: identification of a potential therapeutic window. Br J Ophthalmol. 2002;86(4):448–452. DOI: 10.1136/bjo.86.4.448

22. Missotten G.S., Notting I.C., Schlingemann R.O. Vascular endothelial growth factor a in eyes with uveal melanoma. Arch Ophthalmol. 2006;124:1428–1434 DOI: 10.1001/archopht.124.10.1428

23. Sheidow T.G., Hooper P.L., Crukley C., Young J., Heathcote J.G. Expression of vascular endothelial growth factor in uveal melanoma and its correlation with metastasis. Br J Ophthalmol. 2000;84:750–756. DOI: 10.1136/bjo.84.7.750

24. Claffey K.P., Brown L.F., del Aguila L.F. Expression of vascular permeability factor/ vascular endothelial growth factor by melanoma cells increases tumor growth, angiogenesis, and experimental metastasis. Cancer Res. 1996;56:172–181.

25. Frenkel B.V., Kalickman S., Pe’er J. VEGF as a biomarker for metastatic uveal melanoma in humans. Curr Eye Res. 2011;36(4):386–390. DOI: 10.3109/02713683.2010.534573